Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Adults
Jiaye Liu, Ibrahim Ayada, Xiaofang Zhang, et al.
Clinical Gastroenterology and Hepatology (2021) Vol. 20, Iss. 3, pp. e573-e582
Open Access | Times Cited: 155

Showing 1-25 of 155 citing articles:

Global Prevalence and Clinical Characteristics of Metabolic-associated Fatty Liver Disease: A Meta-Analysis and Systematic Review of 10 739 607 Individuals
Kai En Chan, Tiffany Jia Ling Koh, Ansel Shao Pin Tang, et al.
The Journal of Clinical Endocrinology & Metabolism (2022) Vol. 107, Iss. 9, pp. 2691-2700
Open Access | Times Cited: 184
Hyodeoxycholic acid alleviates non-alcoholic fatty liver disease through modulating the gut-liver axis
Junliang Kuang, Jieyi Wang, Yitao Li, et al.
Cell Metabolism (2023) Vol. 35, Iss. 10, pp. 1752-1766.e8
Open Access | Times Cited: 114
Non-alcoholic fatty liver disease: Definition and subtypes
Seulki Han, Soon Koo Baik, Moon Young Kim
Clinical and Molecular Hepatology (2022) Vol. 29, Iss. Suppl, pp. S5-S16
Open Access | Times Cited: 107
MAFLD: a multisystem disease
Rosaria Maria Pipitone, Carlo Ciccioli, Giuseppe Infantino, et al.
Therapeutic Advances in Endocrinology and Metabolism (2023) Vol. 14
Open Access | Times Cited: 97
The Effects of Probiotics, Prebiotics and Synbiotics in Non-Alcoholic Fat Liver Disease (NAFLD) and Non-Alcoholic Steatohepatitis (NASH): A Systematic Review
Rodrigo Zamignan Carpi, Sandra Maria Barbalho, Kátia Portero Sloan, et al.
International Journal of Molecular Sciences (2022) Vol. 23, Iss. 15, pp. 8805-8805
Open Access | Times Cited: 87
Nonalcoholic Fatty Liver Disease and Cardiovascular Disease: a Review of Shared Cardiometabolic Risk Factors
Emir Muzurović, Carol Chiung‐Hui Peng, Matthew J. Belanger, et al.
Hypertension (2022) Vol. 79, Iss. 7, pp. 1319-1326
Closed Access | Times Cited: 84
WFUMB Guideline/Guidance on Liver Multiparametric Ultrasound: Part 1. Update to 2018 Guidelines on Liver Ultrasound Elastography
Giovanna Ferraioli, R. Graham Barr, Annalisa Berzigotti, et al.
Ultrasound in Medicine & Biology (2024) Vol. 50, Iss. 8, pp. 1071-1087
Closed Access | Times Cited: 31
The role of dietary modification in the prevention and management of metabolic dysfunction-associated fatty liver disease: an international multidisciplinary expert consensus
Xufen Zeng, Krista A Varady, Xiangdong Wang, et al.
Metabolism (2024) Vol. 161, pp. 156028-156028
Closed Access | Times Cited: 20
MAFLD: Exploring the Systemic Effects Beyond Liver.
Utkarsh Dayal, Ujjwal Soni, Sourav Bansal, et al.
Journal of Community Hospital Internal Medicine Perspectives (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 1
Current Options and Future Directions for NAFLD and NASH Treatment
Chunye Zhang, Ming Yang
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 14, pp. 7571-7571
Open Access | Times Cited: 73
Metabolic Dysfunction-associated Fatty Liver Disease and Mortality Among Chinese Adults: a Prospective Cohort Study
Xiaomo Wang, Shouling Wu, Xiaojie Yuan, et al.
The Journal of Clinical Endocrinology & Metabolism (2021) Vol. 107, Iss. 2, pp. e745-e755
Open Access | Times Cited: 65
Metabolic dysfunction-associated fatty liver disease: a year in review
Jawaher Alharthi, Amalia Gastaldelli, Ian Homer, et al.
Current Opinion in Gastroenterology (2022) Vol. 38, Iss. 3, pp. 251-260
Closed Access | Times Cited: 62
Risk stratification and early detection biomarkers for precision HCC screening
Yi‐Te Lee, Naoto Fujiwara, Ju Dong Yang, et al.
Hepatology (2022), pp. n/a-n/a
Open Access | Times Cited: 53
Mapping global epidemiology of thyroid nodules among general population: A systematic review and meta-analysis
Chunyang Mu, Xin Ming, Ye Tian, et al.
Frontiers in Oncology (2022) Vol. 12
Open Access | Times Cited: 50
Therapeutic Activity of Green Tea Epigallocatechin-3-Gallate on Metabolic Diseases and Non-Alcoholic Fatty Liver Diseases: The Current Updates
Armachius James, Ke Wang, Yousheng Wang
Nutrients (2023) Vol. 15, Iss. 13, pp. 3022-3022
Open Access | Times Cited: 36
Metabolic-Dysfunction-Associated Fatty Liver Disease and Gut Microbiota: From Fatty Liver to Dysmetabolic Syndrome
Ludovico Abenavoli, Giuseppe Guido Maria Scarlata, Emidio Scarpellini, et al.
Medicina (2023) Vol. 59, Iss. 3, pp. 594-594
Open Access | Times Cited: 28
Non-Alcoholic Fatty Liver Disease or Type 2 Diabetes Mellitus—The Chicken or the Egg Dilemma
Marcin Kosmalski, Agnieszka Śliwińska, Józef Drzewoski
Biomedicines (2023) Vol. 11, Iss. 4, pp. 1097-1097
Open Access | Times Cited: 25
MAFLD: an optimal framework for understanding liver cancer phenotypes
Harry Crane, Cameron Gofton, Ankur Sharma, et al.
Journal of Gastroenterology (2023) Vol. 58, Iss. 10, pp. 947-964
Open Access | Times Cited: 23
New Insights into the Pathogenesis of Metabolic-Associated Fatty Liver Disease (MAFLD): Gut–Liver–Heart Crosstalk
Keungmo Yang, Myeong Jun Song
Nutrients (2023) Vol. 15, Iss. 18, pp. 3970-3970
Open Access | Times Cited: 22
Cumulative effects of excess high-normal alanine aminotransferase levels in relation to new-onset metabolic dysfunction-associated fatty liver disease in China
Jingfeng Chen, Zhuo-Qing Wu, H. Liu, et al.
World Journal of Gastroenterology (2024) Vol. 30, Iss. 10, pp. 1346-1357
Open Access | Times Cited: 12
Association of metabolic-dysfunction associated steatotic liver disease with polycystic ovary syndrome
Qiuyu Xu, Jie Zhang, Yan Lü, et al.
iScience (2024) Vol. 27, Iss. 2, pp. 108783-108783
Open Access | Times Cited: 11
Non-Pharmacological Approach to Diet and Exercise in Metabolic-Associated Fatty Liver Disease: Bridging the Gap between Research and Clinical Practice
Hassam Ali, Muhammad Shahzil, Vishali Moond, et al.
Journal of Personalized Medicine (2024) Vol. 14, Iss. 1, pp. 61-61
Open Access | Times Cited: 10
Inflammatory Indices and MAFLD Prevalence in Hypertensive Patients: A Large-Scale Cross-Sectional Analysis from China
Di Shen, Xintian Cai, Junli Hu, et al.
Journal of Inflammation Research (2025) Vol. Volume 18, pp. 1623-1638
Open Access | Times Cited: 1
Estimating Global Prevalence of Metabolic Dysfunction-Associated Fatty Liver Disease in Overweight or Obese Children and Adolescents: Systematic Review and Meta-Analysis
Jiaye Liu, Chunyang Mu, Kewei Li, et al.
International Journal of Public Health (2021) Vol. 66
Open Access | Times Cited: 53
Liver Fibrosis in Asians With Metabolic Dysfunction–Associated Fatty Liver Disease
Won Sohn, Heon‐Ju Kwon, Yoosoo Chang, et al.
Clinical Gastroenterology and Hepatology (2021) Vol. 20, Iss. 5, pp. e1135-e1148
Open Access | Times Cited: 45
Page 1 - Next Page

Scroll to top